Patients with colon cancer who still have cancer cells in their blood after surgery may improve their survival odds with ...

Recent research indicates that colon cancer patients with circulating tumor DNA post-surgery may improve their survival likelihood with daily celecoxib use. Celecoxib, a COX-2 inhibitor, significantly ...

New data from two studies presented at ASCO GI 2025 demonstrated that ctDNA testing could predict recurrence risk in ...

A recent analysis from a randomized clinical trial conducted by researchers at the Dana-Farber Brigham Cancer Center ...

Leerink Partners analyst Puneet Souda has maintained their bullish stance on NTRA stock, giving a Buy rating yesterday.Invest with Confidence: ...

A study finds that celecoxib improves disease-free survival in stage 3 colon cancer patients with positive ctDNA after ...

An analysis of ctDNA testing for early detection of recurrence showed that test had high sensitivity across multiple sites of ...

Natera has reported the latest data from the Phase III CALGB (Alliance)/SWOG 80702 study, indicating that Signatera, a ...

In addition to ZTlido, Scilex's portfolio features Elyxyb, an oral celecoxib solution for migraines, which may also find broader use for acute pain such as tension headaches. Another product ...